Buscar
Mostrando ítems 31-40 de 14236
High-throughput Drug Repositioning for the Discovery of New Treatments for Chagas Disease
(Bentham Science Publishers, 2015-03)
Despite affecting around 8 million people worldwide and representing an economic burden above $7 billion/ year, currently approved medications to treat Chagas disease are still limited to two drugs, nifurtimox and benznidazole, ...
Investigación y desarrollo de nuevos medicamentos: de la molécula al fármaco
(Sociedad Médica de Santiago, 2001)
Estratégias biotecnológicas para a liberação controlada de antígenos e adjuvantes em vacinas através de lipossomas
(2006-10-01)
Liposomes (LP) are colloidal systems with ability to compartmentalize therapeutic molecules in order to improve biological activity, decreases the potential toxicity, and to obtain prolonged effect. In this work it was ...
Comparison of impurity profiles of lipiblock® vs. orlistat using HPLC and LC-MS/MS
(2012-04-30)
Comparative HPLC-UV and LC-MS/MS studies of impurity profiles of a reference sample (Xenical®, F. Hoffmann-La Roche Ltd., Switzerland) vs. generic (Lipiblock®, EMS-Sigma Pharma, a generic drug) were carried out with ethanol ...
MRSA infections: from classical treatment to suicide drugs
(Bentham Science Publishers, 2014-02)
Infections caused by the methicillin-resistant Staphylococcus aureus (MRSA) are today a major burden in nosocomial disease control. The global trend shows an alarming increase of MRSA infections as well as multi-drug ...
Potenciais interações medicamentosas responsáveis por internações hospitalares
(2013-04-01)
Drug-drug interactions (DDI) are considered a public health problem, since they may be the cause of negative outcomes for drug users. Research objectives: 1) estimate the prevalence of hospital admissions arising from ...